2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia Meeting Abstract


Authors: Hallek, M.; Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Eradat, H.; Erwin, T.; Lamanna, N.; Coiffier, B.; Pettitt, A. R.; O'Brien, S. M.; Ruppert, S.; Schuster, A.; Kronig, H.
Abstract Title: 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia
Meeting Title: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
Journal Title: Oncology Research and Treatment
Volume: 37
Issue: Suppl.5
Meeting Dates: 2014 Oct 10-14
Meeting Location: Hamburg, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2014-10-01
Start Page: 183
Language: English
ACCESSION: WOS:000343816900444
PROVIDER: wos
PUBMED: 25301272
DOI: 10.1159/000368945
Notes: Meeting Abstract: V568 -- Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology -- 5 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz